Comprehensive Computational Analysis of Honokiol Targets for Cell Cycle Inhibition and Immunotherapy in Metastatic Breast Cancer Stem Cells

Figure 2

(a) Gene ontology (GO) analysis of potential therapeutic targets of honokiol (PTTH) results using WebGestalt. (b) Overview of genetic alterations in CCND1, SIRT2, AURKB, VEGFA, HDAC1, CASP9, HSP90AA1, and HSP90AB1 based in samples from several breast cancer studies. (c) Oncoprint analysis of CCND1, SIRT2, AURKB, VEGFA, HDAC1, CASP9, HSP90AA1, and HSP90AB1 on The Metastatic Breast Cancer Project (Provisional, February 2020) dataset. (d) mRNA expression levels of CCND1, SIRT2, AURKB, VEGFA, HDAC1, CASP9, HSP90AA1, and HSP90AB1 on the Metastatic Breast Cancer Project (Provisional, February 2020) as analyzed using cBioportal. 1: deep deletion, 2: shallow deletion, 3: diploid; 4: gain; 5: amplification. Statistical analyses were done by one-way ANOVA using Tukey’s multiple comparison test. The symbol ororor symbolizes or or or , respectively. (e) Pathways related to genetic alterations predicted by cBioportal. The results showed that genetic alterations of the PTTH disrupted the pathways regulating the cell cycle.

(a)

(b)

(c)

(d)

(e)